Accepted for Publication: July 31, 2020.
Published Online: November 4, 2020. doi:10.1001/jamapsychiatry.2020.3285
Correction: This article was corrected on February 10, 2021, to fix errors in the Abstract Results and Results section.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Davis AK et al. JAMA Psychiatry.
Corresponding Authors: Alan K. Davis, PhD (davis.5996@osu.edu), and Roland R. Griffiths, PhD (rgriff@jhmi.edu), Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224.
Author Contributions: Drs Davis and Griffiths had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Davis, Barrett, May, Cosimano, Johnson, Griffiths.
Acquisition, analysis, or interpretation of data: Davis, Barrett, May, Sepeda, Johnson, Finan, Griffiths.
Drafting of the manuscript: Davis, Barrett, May, Cosimano, Sepeda, Griffiths.
Critical revision of the manuscript for important intellectual content: Davis, Barrett, May, Sepeda, Johnson, Finan, Griffiths.
Statistical analysis: Davis, Griffiths.
Obtained funding: Barrett, Griffiths.
Administrative, technical, or material support: Davis, Barrett, May, Cosimano, Sepeda, Finan, Griffiths.
Supervision: Davis, Barrett, May, Cosimano, Johnson, Griffiths.
Conflict of Interest Disclosures: Dr Davis reported being a board member at Source Research Foundation. Dr Johnson reported receiving grants from Heffter Research Institute outside the submitted work and personal fees as a consultant and/or advisory board member from Beckley Psychedelics Ltd, Entheogen Biomedical Corp, Field Trip Psychedelics Inc, Mind Medicine Inc, and Otsuka Pharmaceutical Development & Commercialization Inc. Dr Griffiths reported being a board member at Heffter Research Institute and receiving grants from Heffter Research Institute outside the submitted work. No other disclosures were reported.
Funding/Support: This study was funded in part by a crowd-sourced funding campaign organized by Tim Ferriss; a grant from the Riverstyx Foundation; and grants from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, Blake Mycoskie, and the Steven and Alexandra Cohen Foundation. Drs Davis and May were supported by postdoctoral training grant T32DA07209 from NIDA. Dr Finan was supported by grant K23DA035915 from NIDA. Drs Griffiths and Johnson were partially supported by grant R01DA03889 from NIDA. The Center for Psychedelic and Consciousness Research is funded by the Steven and Alexandra Cohen Foundation and has received support from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Annie Umbricht, MD, and Eric Strain, MD, provided medical oversight during the study sessions. Jessiy Salwen, PhD, and Mary Bailes, LCPC, served as blinded clinician raters. Natalie Gukasyan, MD; Laura Doyle, BA; John Clifton, BS; Kasey Cox, MS; and Rhiannon Mayhugh, PhD, facilitated the intervention sessions. These individuals, from Johns Hopkins University, received no additional compensation, outside of their usual salary, for their contributions.
Data Sharing Statement: See Supplement 3.
4.Greenberg
PE , Fournier
A-A , Sisitsky
T , Pike
CT , Kessler
RC . The economic burden of adults with major depressive disorder in the United States (2005 and 2010).
J Clin Psychiatry. 2015;76(2):155-162. doi:
10.4088/JCP.14m09298
PubMedGoogle ScholarCrossref 6.Morilak
DA , Frazer
A . Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders.
Int J Neuropsychopharmacol. 2004;7(2):193-218. doi:
10.1017/S1461145704004080
PubMedGoogle ScholarCrossref 7.Gaynes
BN , Warden
D , Trivedi
MH , Wisniewski
SR , Fava
M , Rush
AJ . What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.
Psychiatr Serv. 2009;60(11):1439-1445. doi:
10.1176/ps.2009.60.11.1439
PubMedGoogle ScholarCrossref 8.Nemeroff
CB . Prevalence and management of treatment-resistant depression.
J Clin Psychiatry. 2007;68(suppl 8):17-25.
PubMedGoogle ScholarCrossref 16.Griffiths
RR , Johnson
MW , Carducci
MA ,
et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.
J Psychopharmacol. 2016;30(12):1181-1197. doi:
10.1177/0269881116675513
PubMedGoogle ScholarCrossref 17.Ross
S , Bossis
A , Guss
J ,
et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
J Psychopharmacol. 2016;30(12):1165-1180. doi:
10.1177/0269881116675512
PubMedGoogle ScholarCrossref 23.Studerus
E , Kometer
M , Hasler
F , Vollenweider
FX . Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
J Psychopharmacol. 2011;25(11):1434-1452. doi:
10.1177/0269881110382466
PubMedGoogle ScholarCrossref 24.First
MB , Williams
JBW , Karg
RS , Spitzer
RL . Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). American Psychiatric Association; 2016.
32.Griffiths
RR , Richards
WA , McCann
U , Jesse
R . Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Psychopharmacology (Berl). 2006;187(3):268-283. doi:
10.1007/s00213-006-0457-5
PubMedGoogle ScholarCrossref 33.Griffiths
RR , Johnson
MW , Richards
WA , Richards
BD , McCann
U , Jesse
R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Psychopharmacology (Berl). 2011;218(4):649-665. doi:
10.1007/s00213-011-2358-5
PubMedGoogle ScholarCrossref 34.First
MB , Williams
JBW , Benjamin
LS , Spitzer
RL . Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ). American Psychiatric Association; 2016.
35.First
MB , Williams
JBW , Benjamin
LS , Spitzer
RL . User’s Guide for the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD). American Psychiatric Association; 2016.
36.Morey
LC . Personality assessment inventory (PAI). In: Cautin
RL , Lilienfeld
SO , eds.
The Encyclopedia of Clinical Psychology. John Wiley & Sons, Inc; 2015:1-10. doi:
10.1002/9781118625392.wbecp284 37.International Society for CNS Drug Development. GRID-HAMD-17 Structured Interview Guide. ISCDD; 2003.
39.Rush
AJ , Trivedi
MH , Ibrahim
HM ,
et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
Biol Psychiatry. 2003;54(5):573-583. doi:
10.1016/S0006-3223(02)01866-8
PubMedGoogle ScholarCrossref 42.Posner
K , Brent
D , Lucas
C ,
et al. Columbia-Suicide Severity Rating Scale (C-SSRS). Columbia University Medical Center; 2008.
43.Posner
K , Brown
GK , Stanley
B ,
et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.
Am J Psychiatry. 2011;168(12):1266-1277. doi:
10.1176/appi.ajp.2011.10111704
PubMedGoogle ScholarCrossref 45.Spielberger
CD , Gorsuch
RL , Lushene
R , Vagg
PR , Jacobs
GA . Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press; 1983.
46.Corp
IBM . IBM SPSS Statistics for Windows. Version 25. IBM Corp; 2018.
52.Griffiths
RR , Johnson
MW , Richards
WA ,
et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
J Psychopharmacol. 2018;32(1):49-69. doi:
10.1177/0269881117731279
PubMedGoogle ScholarCrossref 55.Garcia-Romeu
A , Davis
AK , Erowid
E , Erowid
F , Griffiths
RR , Johnson
MW . Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey.
Front Psychiatry. 2020;10:955. doi:
10.3389/fpsyt.2019.00955
PubMedGoogle ScholarCrossref 60.Cuijpers
P , van Straten
A , Warmerdam
L , Andersson
G . Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis.
Depress Anxiety. 2009;26(3):279-288. doi:
10.1002/da.20519
PubMedGoogle ScholarCrossref 61.Cuijpers
P , Sijbrandij
M , Koole
SL , Andersson
G , Beekman
AT , Reynolds
CF
III . Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis.
World Psychiatry. 2014;13(1):56-67. doi:
10.1002/wps.20089
PubMedGoogle ScholarCrossref